Nebokitug
AssetAntibodyAlso CM-101, anti-human CCL24 monoclonal antibody, ABATE
Monoclonal antibody neutralizing CCL24 to reduce inflammation and fibrosis
- Stage
- Phase 2
- Modality
- Antibody
- Target
- Inflammation
- Indications
- 4
- Trials
- 4
- Developers
- 1
Indications
4Nonalcoholic steatohepatitis
Phase 2COMPLETEDNCT05824156clinicaltrials.gov7 Oct 2026
Primary sclerosing cholangitis
Phase 2investors.chemomab.com7 Oct 2026
Systemic sclerosis
Phase 2SUSPENDEDNCT06210945clinicaltrials.gov7 Oct 2026
1 more
- Targets and what it contains2
- Owner and partners1
- Trials4
- Evidence for its targets1
- Competitors1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 5 sources